<DOC>
	<DOCNO>NCT00289627</DOCNO>
	<brief_summary>The purpose clinical research study evaluate Best Overall Response Rate ( BORR ) , ( per modify WHO criterion ) patient previously treat melanoma-Stage III ( unresectable ) Stage IV melanoma receive 10 mg/kg ipilimumab . The safety product also evaluate .</brief_summary>
	<brief_title>A Single Arm Study Ipilimumab Monotherapy Patients With Previously Treated Unresectable Stage III IV Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients previously treat Stage III ( unresectable ) Stage IV melanoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Previously treat melanoma</keyword>
	<keyword>Unresectable Stage III</keyword>
	<keyword>Stage IV</keyword>
</DOC>